Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this pilot study is to investigate if a cognitive treatment targeting obsessive beliefs in patients with aggressive obsessions is feasible and effective as an online treatment.
Patients with obsessive-compulsive disorder who presents with aggressive obsessions (also known as taboo thoughts e.g. fear of being a pedophile) and mental rituals have shown to respond less well to treatment. Thus, there is room for further innovation. The primary objective of this pilot study is to investigate if an internet-based cognitive therapy (I-CT) is feasible and effective in reducing the frequency and distress of aggressive obsessions. The study will also investigate if I-CT is associated with any significant side effects. Another objective of this study is to get a power estimate of the treatment effects for a subsequent randomized controlled study (RCT). This will be done by using an open pilot study with repeated measurements.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Online Cognitive Therapy (I-CT) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Online cognitive therapy (I-CT) | Other | The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual "The treatment of Obsessions" by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform. |
| Measure | Description | Time Frame |
|---|---|---|
| The clinician rated Yale Brown Obsessive Compulsive Scale (Y-BOCS) | Change in obsessions and compulsions from baseline to week 10 and 6 months after treatment has ended. Minimum value is 0. Maximum value is 40. Higher score means more symptoms. | Week 0, week 10, and 6 months follow up |
| Measure | Description | Time Frame |
|---|---|---|
| The self-rated Yale Brown Obsessive Compulsive Scale (Y-BOCS) | Change in obsessions and compulsions from baseline, during treatment to week 10 and at 6 after treatment has ended. Minimum value is 0. Maximum value is 40. Higher score means more symptoms. | Weeks 0 to 10 through treatment and 6 months follow-up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erik Andersson, PhD | Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska Institutet | Stockholm | 17177 | Sweden |
Not provided
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| D009770 | Obsessive Behavior |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Personal Significance Scale (PSS) |
Change in perceived personal significance of intrusive thougths from baseline, during treatment to week 10 and at 6 months after treatment has ended. Minimum value is 0. Maximum value is 80. Higher score means more symptoms. |
| Weeks 0 to 10 through treatment and 6 months follow-up |
| Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S) | Change in depression from baseline to week 10 and at 6 months after treatment has ended. Minimum value is 0. Maximum value is 40. Higher score means more symptoms. | Week 0, week 10 and 6 months follow-up |
| Clinical Global Impression (CGI) | Change in symptom severity from baseline to week 10 and 6 months after treatment has ended, and treatment response and the efficacy of treatments at week 10 and 6 months after treatment after treatment has ended. Rated by the psychologist. Minimum value is 0. Maximum value is 6. Higher score means less improvement. | Week 0, week 10 and 6 months follow-up |
| Work and social adjustment scale (WSAS) | Change in functional impairment from baseline to week 10 and 6 months after treatment has ended. Minimum value is 0. Maximum value is 40. Higher score means more symptoms. | Week 0, week 10 and 6 months follow-up |
| Thought Action Fusion Scale (TAFS) | Change in maladaptive cognitive intrusions from baseline to week 10 and 6 months after treatment has ended. Minimum value is 0. Maximum value is 76. Higher score means more symptoms. | Week 0, week 10 and 6 months follow-up |
| Penn State Worry Questionnaire (PSWQ) | Change in worry from baseline to week 10 and 6 months after treatment has ended. Minimum value is 0. Maximum value is 80. Higher score means more symptoms. | Week 0, week 10 and 6 months follow-up |
| Meta-Cognitive Questionnaire (Negative metacognitions subscale; MCQ-NC) | Change in negative meta-cognitions about worrying from baseline to week 10 and 6 months after treatment has ended. Minimum value is 0. Maximum value is 24. Higher score means more symptoms. | Week 0, week 10 and 6 months follow-up |
| Patient Satisfaction Questionnaire (PSQ) | Satisfaction of treatment at week 10. Qualitative questions. | Week 10 |
| Adverse events (AE) | Number of adverse events every week during treatment and post treatment week 10. | Weeks 0 to 10 through treatment and 6 months follow-up |